Abstract
Systemic delivery of mesenchymal stem cells (MSC) has shown efficacy in animal models and in a phase I clinical trial in suppressing periaortic inflammation and abdominal aortic aneurysm (AAA) expansion. There is evidence that a significant number of MSCs are sequestered in the pulmonary circulation after intravenous (IV) delivery, thus limiting their potency. We hypothesize that delivery of MSCs into periaortic lymph nodes will more effectively enhance the regulatory immune response and thus more effectively suppress aneurysm formation as compared to IV administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
